Despite setbacks and funding cuts — and a quieting of the hype blaring its arrival — multiple CRISPR-based trials are ...

CRISPR Therapeutics recently presented new preclinical data at the ESGCT 2025 Annual Congress showing its investigational CTX460, using the SyNTase gene editing platform, achieved greater than 90% ...

On June 28, 2012, the most significant scientific breakthrough of the first quarter of the 21st century was announced to the ...

The world's first patient to be treated with personalized gene editing therapy is finally headed home after over 300 days in the hospital. Nine-month-old KJ Muldoon recently underwent CRISPR-based ...

CRISPR-based tools can’t easily access the DNA in these organelles, but researchers are finding other ways in.

PHILADELPHIA (WPVI) -- After 307 days at the Children's Hospital of Philadelphia, a local baby who was born with a rare and usually fatal disorder is now at home. It's all thanks to a pioneering ...

CRISPR Therapeutics’ stock is surging as in-vivo therapies show promise. Learn about CRSP stock's risks, long-term upside, ...

One of the most revolutionary tools in cutting-edge medicine is a molecular scalpel so precise that it can modify defective ...

A ten-month-old baby who has been at the Children's Hospital of Philadelphia (CHOP) since birth finally got to go home with his family. KJ Muldoon made headlines around the globe a few weeks ago for ...

Preclinical data presented at the European Society of Gene and Cell Therapy (ESGCT) highlight a potential best-in-class ...

The Influenza A virus (IAV) has been the cause of six major flu pandemics, responsible for 50 to 100 million deaths globally.